Research
Hormonal
Tirzepatide can achieve weight loss of up to 22.5% at the highest doses.
Tirzepatide represents a potent option for significant weight loss in obese patients.
StrongSupportsmedium confidence
Tirzepatide (un agonista dual del receptor GLP-1/GIP) consigue una pérdida de peso de hasta un 22,5% en las dosis más altas.
Why this rating
The claim is based on clinical data regarding tirzepatide's efficacy.
Source
Weight management treatment in obesity
Miguel A. Rubio et al. · Medicina Clínica (English Edition) · 2025
DOI 10.1016/j.medcle.2025.107152
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →